Immunotherapy Trials Surge, Study Targets Cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Immunotherapy trials rose from 1,257 between 2006‑2016 to 4,591 in the past decade, reflecting rapid research expansion.
- Checkpoint inhibitors reactivate immune cells to attack tumors, and dozens are approved for more than 30 cancer types.
- Herceptin binds to breast and stomach tumors, flagging them for immune destruction and blocking growth signals.
- CAR‑T therapy has produced dramatic remissions, exemplified by actor Sam Neill becoming cancer‑free after treating stage 3 blood cancer in a trial.
- Four‑year study will enroll thousands of patients with breast, bladder, kidney and skin cancers to identify factors that influence immunotherapy outcomes.
Why it matters: Patients with breast, bladder, kidney and skin cancers will gain clearer guidance on effective immunotherapies, while pharmaceutical companies will see more precise targets for drug development, accelerating approval and access.
